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Background/Aim: Hepatitis D virus (HDV) superinfection in patients with chronic hepatitis B leads to
accelerated liver injury, early cirrhosis, and decompensation. It may be speculated that hepatocellular
carcinoma (HCC) may differ in these patients from hepatitis B virus (HBV) monoinfection. The aim of
this study was to compare clinical aspects of hepatocellular carcinoma in patients of hepatitis D with HBV
monoinfection. Patients and Methods: A total of 92 consecutive HCC cases seropositive for antibody against
HDV antigen (HDV group) were compared with 92 HBsAg-positive and anti-HDV-negative cases (HBV
group). Results: The features including sex, body mass index, presence of ascites, serum biochemistry,
gross tumor appearance, child class, barcelona cancer liver clinic and okuda stages were not significantly
different between the 2 groups. Decreased liver size was noticed more in cases of HDV compared with HBV
group where the liver size was normal or increased (P=0.000). HDV patients had lower platelets (P=0.053)
and larger varices on endoscopy (P=0.004). Multifocal tumors and elevated alpha-fetoprotein level >1000
IU/mL were more common in HBV group (P=0.040 and P= 0.061). TNM classification showed more stage
III–IV disease in HBV group (P=0.000). Conclusion: Decreased liver size and indirect evidence of more
severe portal hypertension and earlier TNM stage compared with HBV monoinfection indicate that HDV
infection causes HCC in a different way, possibly indirectly by inducing inflammation and cirrhosis.
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Chronic hepatitis B is a major cause of cirrhosis, hepatocellular
carcinoma (HCC), and liver-related mortality worldwide.
Coinfection with hepatitis D virus (HDV) is associated
with more severe liver disease and poor prognosis.[1-3] HDV
is a defective RNA virus that requires hepatitis B virus
(HBV) as helper virus.[4] Two viruses share the same route
of transmission, being transmitted by contaminated blood
and body fluids. HDV can infect simultaneously with HBV
(coinfection) or in a patient with already established HBV
infection (superinfection).
Although the incidence of HDV infection has decreased in the
endemic countries as a result of effective immunoprophylaxis
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against HBV and improvement in socioeconomic and hygienic
conditions,[5-7] it remains a relevant cause of morbidity in the
Asia Pacific region.[8] There is no satisfactory treatment of
hepatitis D. HDV infection is a critical problem in our country. It
is present in 16.6% of hepatitis B–infected patients in Pakistan,
most commonly in younger males living in rural areas.[9]
HDV infection increases the risk for HCC threefold
and mortality twofold in patients with HBsAg-positive
cirrhosis.[10] In a study from Japan the overall relative risk for
liver cirrhosis and HCC was 2.58 and 2.87, respectively.[11]
However, these findings were contradicted by a retrospective
analysis of 962 HBV patients that showed similar rates
of HCC in the 82 HDV-infected patients and 880 noninfected patients.[12] According to another study, persistent
HDV replication leads to cirrhosis and HCC at annual
rates of 4% and 2.8%, respectively, and is the only predictor
of liver-related mortality.[13] The aim of this study was to
compare clinical features and tumor characteristics of HCC
in hepatitis D antibody–positive patients with hepatitis B
monoinfection in an Asian country with a high prevalence
of HDV infection.
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PATIENTS AND METHODS
All adult patients (age ≥18 years) with HCC associated
with chronic HDV infection who were admitted under
Gastroenterology Hepatology Services in a tertiary care
hospital between January 1999 and June 2009 were identified
by ICD coding. These consecutive cases were reviewed and
compared with consecutive HBV monoinfection-related
HCC patients who were positive for HBsAg, but seronegative
for HDV and managed during the same time period.
Due to high prevalence of hepatitis D, it is an institutional
policy to rule out hepatitis D in every case of hepatitis B.
HBV and HDV infections were diagnosed by commercially
available enzyme-linked immunosorbent assays for HBsAg
and anti-HDV antibody. Antibody to hepatitis C virus was
assayed by a third-generation test system. Patients were
labeled as suffering from HBV monoinfection if antibodies
for both hepatitis C and D were found negative in a patient
with reactive HBsAg. The diagnosis of HCC was defined as
either the presence of a hepatic lesion >2cm in diameter
on triphasic CT with typical vascular pattern for HCC
(hypervascular with washout in the portal/venous phase) with
or without elevated alpha-fetoprotein >200 ng/mL or the
presence of a lesion1–2 cm in diameter with typical vascular
pattern for HCC on two dynamic imaging techniques.[14]
Demographic data (age, sex, body mass index were
extracted from patients’ records. Patients with cirrhosis
were identified based on clinical features of cirrhosis and/
or radiologic evidence of cirrhosis in the context of portal
hypertension (ascites, varices, thrombocytopenia, or hepatic
encephalopathy). Patient data from the first clinic visit or
admission with HCC were used to calculate Child–Turcotte–
Pugh score and stage of HCC by Okuda,[15] Barcelona Cancer
Liver Clinic (BCLC),[16] and TNM staging systems.[17] Alphafetoprotein levels during the same admission were also noted.
All of these patients underwent ultrasound examination
followed by a triphasic CT scan.
Ultrasound examinations were carried out by experienced
radiologists with the fasting subjects lying in the supine
position. Measurement of the liver diameter was done in
the right midclavicular line during deep inspiration. The
size of the liver was measured from the hepatic dome to the
inferior hepatic tip. The liver diameter of 12–15 cm was taken
as normal.[18] Numbers of the tumor lesions were counted
from the CT scan.
Endoscopic evaluation of varices was recorded where
available. Endoscopy was performed by the same group of
physicians. Grading system to document the size of varices
being followed in our hospital evaluates varices as follows:

Grade I, varices present but flatten completely with air
insufflations; grade II, nonflatteningvarices that occupy
10%–30% of the esophageal luminal radius; grade III, varices
occupy 31%–60% of the esophageal luminal radius; grade
IV, varices occupy 61%–100% of the esophageal luminal
radius.[19,20] For this study Grade I–II varices were grouped
together as small and Grade III–IV as large varices.

Statistical analysis

Descriptive statistics were computed for all variables. Chisquare test was used for dichotomous variables and Mann–
Whitney U test for continuous variables. P value of less
than 0.05 was taken as significant. SPSS version 17 software
(SPSS, Chicago, IL, USA) was used for all analyses.

RESULTS
Total number of patients of HCC seropositive for HDV
identified were 92 (HDV group). They were compared with
92 consecutive HBsAg positive but anti-HDV negative
HCC cases (HBV group). Combining two groups the study
includes 184 patients, 84% of patients were males (male 155
and females 29). Their age was 54.6 ± 11.1 years (median
55, range 18–85). Most of these patients were in Child class
B or C (A=26, B=76, C=82) with a median Child–Pugh
score of 9 (5–14). Their Okuda stage was II in 106 (57.6%),
III in 54 (29.4%), and I in 24 (13%).
The mean age was not different in both groups of patients
(55.4 years in HDV group and 53.6 in HBV group). Other
features, including sex, presence of ascites, serum biochemistry,
and Child class, were not significantly different between the
two groups [Table 1]. Decreased liver size was noticed more
in cases of HDV compared with HBV group where the liver
size was normal or increased (P=0.000). HDV patients had
lower platelets (P=0.053). Endoscopic evaluation of varices
was available in 77 patients, 39 in the HDV group and 38 in
the HBV group. HDV group had more “large” (grade III–IV)
varices on endoscopy compared with HBV group (P=0.004).
The mean alpha-fetoprotein levels were higher in HBV
patients than in HDV patients (17612 vs 10215). However,
there was no statistically significant difference. More patients
in HBV group had elevated alpha-fetoprotein >1000; P value
of 0.061 though not significant, did show a trend [Table 2].
Multifocal tumors were more common in HBV group
(P=0.040). TNM classification showed more stage III–IV
disease in HBV group (P=0.000),although there was no
difference in Okuda or BCLC stage (P=0.764 and P=1.000).

DISCUSSION
HCC is a substantial complication of liver cirrhosis. It is
recognized that HBV is one of the few human oncogenous
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Table 1: Characteristics of patients with HBV and HDV
hepatocellular carcinoma
Age (years ± SD)
Sex
Male
Female
Body mass index (kg/m2)
Decreased liver size
Splenomegaly
Variceal size
Small/large
ALT (IU/L)
AST (IU/L)
Alkaline phosphatase (IU/L)
GGT (IU/L)
Platelets (×106/L)
Hemoglobin (g/dL)
INR
Serum albumin (g/dL)
Child class
A
B
C
Pugh score

HBV (n=92)
53.6 ± 11.3

HDV (n=92)
55.4 ± 10.8

P value
0.339

75
17
23.9 ± 5.2
23
46

80
12
23.4 ± 5.4
49
52

0.312

16/22
5/34
93.2 ± 101
99.2 ± 94.3
215.3 ± 452 226.2 ± 454.6
195.6 ± 123 187.5 ± 101.4
160.5 ± 144.4 137.7 ± 109.2
169 ± 108
141 ± 86
11.6 ± 2.2
13.6 ± 19.1
1.54 ± 0.54
1.61 ± 0.58
2.45 ± 0.60
2.51 ± 1.15
12
43
37
9.4 ± 2.3

14
33
45
9.2 ± 2.4

0.452
0.000
0.375
0.004
0.714
0.684
0.922
0.394
0.053
0.945
0.410
0.535
0.325

0.724

ALT: Alanine aminotransferase, AST: Aspartate aminotransferase,
GGT: Gamma-glutamyltranspeptidase, HBV: Hepatitis B virus, HDV: Hepatitis
D virus

viruses.[21] HCC incidence is higher in countries where
hepatitis B is endemic. Addition of HDV infection seems
to increase the risk of HCC development. HDV-related
cirrhosis is usually an aggressive disease with a median time
to decompensation less than 2 years and a median survival
less than 5 years.[22] However, as with any immune-mediated
disease, different patterns of progression, ranging from
mild to severe progressive disease, are observed.[23] In these
patients, it is the clinical decompensation and not HCC,
which is the first dominant complication to appear. Severity
of HDV infection may be an important predictor of HCC.
Patients infected with genotype one HDV have a lower
remission rate, more aggressive disease, and more adverse
outcomes (cirrhosis, hepatocellular carcinoma, or mortality)
than those with genotype II HDV.[24,25]
Unfortunately HDV genotype I is prevalent in our country
and in one of our previous studies all the HDV patients
belonged to this genotype.[26] HBV genotype D is prevalent in
about 95% of our HBV patients.[27]Although the information
about genotypes is not available in the present study, it may
be presumed that most of our patients would be harboring
HDV genotype I and HBV genotype D.
Hepatitis viruses may cause HCC through an indirect
mechanism inducing inflammation and cirrhosis,whereas

20
Volume 18, Number 1
Safar 1433H
January 2012

The Saudi Journal of
Gastroenterology

Table 2: Tumor characteristics of HBV and HDV
hepatocellular carcinomas
HBV (n=92)
HDV (n=92) P value
Number of lesions
Solitary
23
36
0.120
2–3
39
31
>3
30
25
Multifocal tumor
69
56
0.040
Size of biggest lesion (cm)
1–3
27
26
0.985
3.1–5
19
19
>5
46
47
Portal vein invasion or
31
29
0.753
thrombosis
Alpha-fetoprotein
(IU/mL)
Mean±S.D.
17612 ± 79474 10215 ± 35563 0.165
Median
208.0
114.0
0.376
Range
1.57–730000 0.83–300000
0.061
>200
49
43
>1000
37
25
BCLC stage
A or B
21
71
1.000
C or D
21
71
Okuda stage
I
10
14
0.457
II
5725
49
III
29
TNM-based stage
I and II
01
17
0.000
III–IV
91
75
BCLC: Barcelona clinic liver cancer, HBV: Hepatitis B virus, HDV: Hepatitis
D virus

HBV has a direct oncogenic potential as well. [28] HBV
DNA integrates into cellular DNA but is not an acutely
transforming virus, because HCC usually develops decades
after infection. Other factors, namely cirrhosis, inflammation,
alcohol intake, and viral superinfections, could promote
the oncogenetic process induced by HBV. HDV infection,
superimposed on the oncogenetic background provided
by chronic HBV infection appears to provide an additional
promotion risk for HCC. Our HDV-positive patients had
decreased liver size and indirect evidence of more severe
portal hypertension and earlier TNM stage compared with
HBV monoinfection, which may indicate that HDV infection
causes HCC possibly indirectly by inducing inflammation
and cirrhosis.
Patients with florid infections from both HBV and HDV and
active liver inflammation should develop HCC at a younger
age than those infected by HBV alone.[29,30]
However, there was no significant age difference in our study.
This may be because in endemic areas HDV may superinfect
at any age and start the aggressive disease leading to cirrhosis
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and eventually HCC. It is also known that active replication
of HBV promotes carcinogenesis[31] and HDV can inhibit
HBV genome and replication[32,33] and could interfere with
cancer development in HDV patients with less aggressive
disease. This ability of HDV to suppress HBV replication
could represent a protective mechanism to lower the risk of
HCC development.
There was much difference in TNM-based staging among
two groups. Our patients of hepatitis B were mostly in
stage III–IV. This may reflect a more aggressive tumor
behavior. This trend is also reflected by a higher number
of HBV group patients having their alpha-fetoprotein level
>1000 IU/mL. On the other hand, early stage in HDV HCC
could be attributable to lead time bias; earlier diagnosis
while investigating early decompensation or more severe
portal hypertension. The latter was reflected in our cases
by decreased liver size, lower platelet count, and larger
varices. However, there was no difference in Child–Pugh
score because this scoring system does not take into account
the above factors. This may also explain why there was no
difference in Okuda staging, which depends on the tumor
size and three measures of the severity of cirrhosis (the
amount of ascites and the serum albumin and bilirubin
levels) included in the Child–Pugh scoring. There was also
no difference in the BCLC staging, which is based on the
extent of the primary lesion, performance status, vascular
invasion, as well as Child class. The patient-centered
approach in this system is more appropriate to segregate
good surgical candidates for resection or radical therapy
from those requiring palliative care while our patients in
both groups presented late.

HBV-DNA and the status of HBe antigen and antibody was
also not available in all cases. The patients were identified
by the ICD coding system leading to the identification of
hospitalized patients, with a severe underlying liver disease
(high prevalence of Child–Pugh C patients), which may
influence the characterization of the tumor. These are
patients with really advanced tumors (small number of
Okuda I patients in both groups). However, it is not possible
to perform a case control prospective study as it would take
years to get sufficient number of cases HDV-positive HCC
cases. However, our findings may be confirmed in a large
prospective multicenter study.
In summary, we have tried to identify some differences in the
presentation of HCC in hepatitis D versus hepatitis B. More
HDV patients have decreased liver size and indirect evidence
of more severe portal hypertension and earlier TNM stage
compared with HBV monoinfection. Multifocal tumors are
more common in hepatitis B. These facts may indicate that
HDV infection possibly causes HCC indirectly by inducing
inflammation and cirrhosis.
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